SBIR/STTR Research Award
Commercialization of an Advanced Technology for T Cell Receptor Analysis and Engineering
Award amount
$265,000Program and phase
SBIR · Phase IAward year
2015Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Gigagen, Inc.
- Proposal award date
- 2015-06-24
- Contract end date
- 2016-05-31
- UEI
- HF7MJJDVQQX5
- Solicitation number
- PA16-019
- Topic code
- NIAID
Research abstract
DESCRIPTION provided by applicant An Advanced Tool for T Cell Analysis Using Microfluidics Organization GigaGen Inc PI David S Johnson Ph D Better methods for discovery and monitoring of immune system biomarkers could improve treatment of a variety of diseases and conditions including cancer autoimmune diseases allergies transplant rejection and infectious diseases We are building a novel technology that uses microfluidics and DNA sequencing to understand the immune system in unprecedented ways PROJECT NARRATIVE Project Title An Advanced Tool for T Cell Analysis Using Microfluidics Organization GigaGen Inc PI David S Johnson Ph D Better methods for discovery and monitoring of immune system biomarkers could improve treatment of a variety of diseases and conditions including cancer autoimmune diseases allergies transplant rejection and infectious diseases We are building a novel technology that uses microfluidics and DNA sequencing to understand the immune system in unprecedented ways
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Production Technology for Recombinant Intravenous Immunoglobulin
- Next-Generation Antibody Discovery and Development Technology
- Recombinant Hyperimmune Gammaglobulin for Primary Immunodeficiency
- Recombinant Hyperimmune Gammaglobulin for Pneumococcal Disease
- Production Technology for Recombinant Intravenous Immunoglobulin
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients
Research funding history
17 SBIR/STTR records share this UEI (2011–2017). Reported award amounts total $10,857,672. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services, National Science Foundation, Department of Energy